Completed PHASE3 INTERVENTIONAL 2-arm NCT00262782

Fludarabine or Observation in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia

Prognostic Factors and Risk-Adapted Therapy in Patients With Early Stage Chronic Lymphocytic Leukemia

Sponsor: German CLL Study Group

Interventions Fludarabine

Updated 8 times since 2017 Last updated: Feb 18, 2020 Started: Apr 30, 1997 Primary completion: Dec 31, 2004 Completion: Jun 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Chronic Lymphocytic Leukemia and is currently completed. German CLL Study Group leads this study, which shows 8 recorded versions since 1997 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Mar 2020 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2019 — Mar 2020 [monthly]

Completed PHASE3
Jun 2018 — Jun 2019 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Apr 1997

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

German CLL Study Group

Data source: German CLL Study Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amberg, Germany , Arnstadt, Germany , Augsburg, Germany , Aurich, Germany , Bad Friedrichshall, Germany , Bad Hersfeld, Germany , Bad Reichenhall, Germany , Bad Saarow, Germany , Bad Urach, Germany , Berlin, Germany and 81 more locations